IP Library › Patent Application 15448238
Patent Application
App. No. 15/448,238

APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/448,238
Abstract

The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.

Claims (9)

1 - 33 . (canceled)

34 . A compound comprising the nucleotide sequence of SEQ ID NO: 2, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 or 66 or a pharmaceutically acceptable salt thereof.

35 . The compound or pharmaceutically acceptable salt thereof of claim 34 conjugated to a polyethylene glycol moiety.

36 . The composition of claim 35 wherein the polyethylene glycol moiety comprises a molecular weight greater than 10 kDa.

37 . The composition of claim 35 wherein the polyethylene glycol moiety comprises a molecular weight of 20 kDa.

38 . The compound or pharmaceutically acceptable salt thereof of claim 37 wherein the nucleotide sequence is SEQ ID NO: 66.

39 . A pharmaceutical composition comprising a therapeutically effective amount of the compound or salt of claim 34 and a pharmaceutically acceptable carrier or vehicle.

40 . A method for treating a C5 complement protein, C5a and/or C5b-9 mediated disorder, the method comprising administering to a patient in need thereof a therapeutically effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 34 .

41 . The method of claim 40 wherein the disorder is complement mediated ocular tissue damage.